Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

The first-in-human SCS trial saw all three SMA patients able to increase their walking distance within six minutes to 20 meters.

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle atrophy (SMA) progression and could be applied to other motoneuron diseases, ...

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop. ... Read More The post Health Check: Percheron ‘closes the ...

Researchers reported what they called the first evidence that a spine-stimulating implant might aid neurodegenerative ...